| 2023 |
Mersha AG, Kennedy M, Eftekhari P, Lee KSK, Upton P, Segan C, et al., 'Using the Behaviour Change Wheel and modified Delphi method to identify behavioural change techniques for improving adherence to smoking cessation medications.', BMC Public Health, 23 1362 (2023) [C1]
|
|
Nova |
| 2023 |
Jackson MA, Brown AL, Baker AL, Bonevski B, Haber P, Bonomo Y, et al., 'Tobacco treatment incorporating contingency management, nicotine replacement therapy, and behavioral counseling for pregnant women who use substances: a feasibility trial.', Front Psychiatry, 14 1207955 (2023) [C1]
|
|
Nova |
| 2022 |
Jackson MA, Buykx P, Brown AL, Baker AL, Dunlop AJ, Gould GS, 'Using mixed methods to establish tobacco treatment acceptability from the perspective of clients and clinicians of antenatal substance use services', ADDICTION SCIENCE & CLINICAL PRACTICE, 17 (2022) [C1]
|
|
Nova |
| 2022 |
Jackson MA, Baker AL, Gould GS, Brown AL, Dunlop AJ, McCarter K, 'Smoking cessation interventions for pregnant women attending treatment for substance use disorders: A systematic review.', Addiction, 117 847-860 (2022) [C1]
|
|
Nova |
| 2022 |
Montebello M, Jefferies M, Mills L, Bruno R, Copeland J, McGregor I, et al., 'Mood, sleep and pain comorbidity outcomes in cannabis dependent patients: Findings from a nabiximols versus placebo randomised controlled trial.', Drug Alcohol Depend, 234 109388 (2022) [C1]
|
|
Nova |
| 2021 |
Jackson MA, Brown AL, Johnston J, Clancy R, McGregor I, Bruno R, et al., 'The use and effects of synthetic cannabinoid receptor agonists by New South Wales cannabis treatment clients.', Journal of cannabis research, 3 33 (2021) [C1]
|
|
Nova |
| 2020 |
Jackson MA, Brown AL, Baker AL, Dunlop AJ, Dunford A, Gould GS, 'Intensive Behavioural and Pharmacological Treatment for Tobacco Dependence in Pregnant Women with Complex Psychosocial Challenges: A Case Report', INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 17 (2020)
|
|
|
| 2019 |
Jackson MA, Baker AL, McCarter KL, Brown AL, Gould GS, Dunlop AJ, 'Interventions for pregnant women who use tobacco and other substances: a systematic review protocol', BMJ OPEN, 9 (2019)
|
|
|
| 2019 |
Jackson MA, Brown AL, Baker AL, Gould GS, Dunlop AJ, 'The Incentives to Quit tobacco in Pregnancy (IQuiP) protocol: Piloting a financial incentive-based smoking treatment for women attending substance use in pregnancy antenatal services', BMJ Open, 9 (2019)
Introduction While tobacco smoking prevalence is falling in many western societies, it remains elevated among high-priority cohorts. Rates up to 95% have been reported in women wh... [more] Introduction While tobacco smoking prevalence is falling in many western societies, it remains elevated among high-priority cohorts. Rates up to 95% have been reported in women whose pregnancy is complicated by other substance use. In this group, the potential for poor pregnancy outcomes and adverse physical and neurobiological fetal development are elevated by tobacco smoking. Unfortunately, few targeted and effective tobacco dependence treatments exist to assist cessation in this population. The study will trial an evidence-based, multicomponent tobacco smoking treatment tailored to pregnant women who use other substances. The intervention comprises financial incentives for biochemically verified abstinence, psychotherapy delivered by drug and alcohol counsellors, and nicotine replacement therapy. It will be piloted at three government-based, primary healthcare facilities in New South Wales (NSW) and Victoria, Australia. The study will assess the feasibility and acceptability of the treatment when integrated into routine antenatal care offered by substance use in pregnancy antenatal services. Methods and analysis The study will use a single-arm design with pre-post comparisons. One hundred clients will be recruited from antenatal clinics with a substance use in pregnancy service. Women must be <33 weeks' gestation, =16 years old and a current tobacco smoker. The primary outcomes are feasibility, assessed by recruitment and retention and the acceptability of addressing smoking among this population. Secondary outcomes include changes in smoking behaviours, the comparison of adverse maternal outcomes and neonatal characteristics to those of a historical control group, and a cost-consequence analysis of the intervention implementation. Ethics and dissemination Protocol approval was granted by Hunter New England Human Research Ethics Committee (Reference 17/04/12/4.05), with additional ethical approval sought from the Aboriginal Health and Medical Research Council of NSW (Reference 1249/17). Findings will be disseminated via academic conferences, peer-reviewed publications and social media. Trial registration number Australia New Zealand Clinical Trial Registry (Ref: ACTRN12618000576224).
|
|
|
| 2018 |
Bhardwaj AK, Allsop DJ, Copeland J, McGregor IS, Dunlop A, Shanahan M, et al., 'Randomised Controlled Trial (RCT) of cannabinoid replacement therapy (Nabiximols) for the management of treatment-resistant cannabis dependent patients: a study protocol', BMC PSYCHIATRY, 18 (2018)
|
|
|
| 2017 |
Dunlop AJ, Brown AL, Oldmeadow C, Harris A, Gill A, Sadler C, et al., 'Effectiveness and cost-effectiveness of unsupervised buprenorphine-naloxone for the treatment of heroin dependence in a randomized waitlist controlled trial', Drug and Alcohol Dependence, 174 181-191 (2017) [C1]
Background Access to opioid agonist treatment can be associated with extensive waiting periods with significant health and financial burdens. This study aimed to determine whether... [more] Background Access to opioid agonist treatment can be associated with extensive waiting periods with significant health and financial burdens. This study aimed to determine whether patients with heroin dependence dispensed buprenorphine-naloxone weekly have greater reductions in heroin use and related adverse health effects 12-weeks after commencing treatment, compared to waitlist controls and to examine the cost-effectiveness of this strategy. Methods An open-label waitlist RCT was conducted in an opioid treatment clinic in Newcastle, Australia. Fifty patients with DSM-IV-TR heroin dependence (and no other substance dependence) were recruited. The intervention group (n = 25) received take-home self-administered sublingual buprenorphine-naloxone weekly (mean dose, 22.7 ± 5.7 mg) and weekly clinical review. Waitlist controls (n = 25) received no clinical intervention. The primary outcome was heroin use (self-report, urine toxicology verified) at weeks four, eight and 12. The primary cost-effectiveness outcome was incremental cost per additional heroin-free-day. Results Outcome data were available for 80% of all randomized participants. Across the 12-weeks, treatment group heroin use was on average 19.02 days less/month (95% CI -22.98, -15.06, p < 0.0001). A total 12-week reduction in adjusted costs including crime of $A5,722 (95% CI 3299, 8154) in favor of treatment was observed. Excluding crime, incremental cost per heroin-free-day gained from treatment was $A18.24 (95% CI 4.50, 28.49). Conclusion When compared to remaining on a waitlist, take-home self-administered buprenorphine-naloxone treatment is associated with significant reductions in heroin use for people with DSM-IV-TR heroin dependence. This cost-effective approach may be an efficient strategy to enhance treatment capacity.
|
|
Nova |
